Simplify Your Path to Optimal Health 3 STEPS TO GET THERE We provide expert-guided, tailored plans to achieve your goals
Researchers such as Johansen suggest that by mimicking this hormone, Ipamorelin may induce the release of growth hormone by anterior pituitary cells but also potentially mediate other actions similar to ghrelin
The earlier we intervene on the precursor disease of multiple diseases, the less PwO need to suffer from the burdensome sequalae of obesity and the better the quality of life our patients with obesity can have
In clinical trials of semaglutide injection for type 2 diabetes mellitus (T2DM), cholelithiasis was reported in 1.5% and 0.4% of patients-treated with semaglutide 0.5 mg and 1 mg subcutaneous injection, respectively
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
calcium supplementation only if dietary intake is inadequate) [4] Nutritional assessment to ensure adequate protein intake during weight loss (minimum 1.0-1.2g/kg body weight) Encouragement of weight-bearing exercise and resistance training to maintain bone strength, in line with UK Chief Medical Officers' Physical Activity Guidelines Medication review to identify and address other factors affecting bone health Repeat fracture risk assessment in high-risk patients, with DXA scanning as clinically indicated based on NICE/NOGG guidance Patients experiencing weight loss faster than planned (particularly if exceeding 0.5-1kg per week sustained over several weeks) should be reviewed to ensure nutritional adequacy and consider whether treatment adjustment is appropriate
